observed in patients with leukaemia have any effect on ATP production and consequently stem cell function. There is the possibility that these mtDNA mutations have a subtle effect on mitochondrial function and this increases the risk of a stem cell becoming malignant. While this view is discussed by Gattermann, 1 the only way to test this hypothesis is to directly measure the mutation load (and spectrum) in haematological stem cells from normal adults and to directly compare with the changes seen in leukaemia.
The discovery of pathogenic mtDNA mutations in MDS patients is intriguing. In Pearson's syndrome, sideroblastic anaemia is prominent and thus it is accepted that a respiratory chain abnormality as a consequence of mtDNA mutation (in this case a single, large-scale mtDNA deletion) can affect blood cell maturation. However, in patients with MDS who have a pathogenic mtDNA mutation, the mutation must be acquired and clonally expand through the haematopoeitic tissues. This would seem remarkable for a cell that has a severely compromised respiratory chain function and is in stark contrast to the observed situation in inherited mtDNA abnormalities in which the mutation is lost in blood. 6 The effect of the respiratory chain defect in MDS therefore seems to be more severe on cell maturation than replication. Do our observations have other important implications? As highlighted by Gattermann, 1 the mitochondrial genome is present in multiple copies in individual cells, thus permitting extensive molecular genetic studies at the level of the single cell. 7, 8 On account of this high copy compared to nuclear gene targets, we believe that somatic mtDNA mutations may prove useful in the detection of malignant leukaemic clones and therefore as markers of disease activity. 2 While we do not directly compare mtDNA markers with nuclear markers of mimimal residual disease in our manuscript, such a study may prove important in the future. A much more long-term goal is also to consider the presence of a somatic, clonal mtDNA mutation as a potential target for treatment. The work of our own group focuses predominantly on the detection and characterisation of inherited mtDNA mutations, a common genetic cause of neurological and neuromuscular conditions that affect at least 1 in 10 000 of the population. 9 In spite of our extensive understanding of the pathogenesis of many of these mtDNA mutations, at present there is little we can offer our patients in terms of treatment. Developing molecules and drugs that can specifically target mutated mtDNA is a priority for patients with mtDNA disease, 10 but any such approach, if successful, may also be of value on treating leukaemia or other malignancies in which there are clonal mtDNA mutations.
In conclusion, we believe our studies have shown convincingly that acquired mtDNA mutations occur in leukaemia. Our paper documents the phenomenology, but further studies are now required to elucidate the significance of these sequence changes in the development of leukaemia. 2 Furthermore, RAS function is not required for the growth of cancer cell lines with the V599E mutation. 2 In leukemias, the RAS-RAF-MEK-ERK-MAP kinase pathway is known to be frequently activated, and the NRAS mutation is partly responsible for this activation. 3 BRAF is well expressed in hematopoietic cells, 4 and expression of activated BRAF can relieve the cytokine dependence and can result in the transformation of hematopoietic cells. [4] [5] [6] To date, there is only one report on BRAF mutation in leukemia samples, which detected no BRAF mutations in acute myelogenous leukemia (AML) FAB type M1 and M2 from the United Kingdom. 7 Because it is possible that other types of acute leukemia or other racial populations with acute leukemia might harbor the BRAF mutation, we investigated the occurrence of BRAF gene mutations in acute leukemias in the Korean adult population.
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Leukemia DNA samples were extracted from the bone marrow of 90 acute leukemia patients (age range 20-80 years). The DNA samples from the same patients were extracted from the bone marrows after complete remission, and used as possible normal genomic DNA samples of the patients. In complete remission, the cellularity of the bone marrow biopsy should be more than 20% with maturation of all cell lines, and the bone marrow should contain less than 5% blast cells. The leukemias consisted of four AMLs minimally differentiated, 12 AMLs without maturation, 23 AMLs with maturation, three acute myelomonocytic leukemias, three acute monoblastic and monocytic leukemias, two acute erythroid leukemias, one AML with t(8;21)(q22;q22), two AMLs with abnormal bone marrow eosinophils, 10 acute promyelocytic leukemias (AML with t(q22;q12)), six AMLs with multilineage dysplasia, 11 biphenotypic acute leukemias, two T-cell acute lymphoblastic leukemias (ALL) and 10 B-cell ALLs according to the WHO classification. Approval for this study was obtained from the Catholic University of Korea, College of Medicine's institutional review board. The genomic DNA each from normal cells or tumor cells was amplified with two primer pairs covering exons 11 and 15 of the BRAF gene, because all of the BRAF mutations have been detected so far in these two exons. Exons 11 and 15 encode the kinase domains in G-loop and the activation segment of BRAF, respectively. 2 Radioisotope was incorporated into the PCR products for detection by autoradiogram. The PCR reaction mixture was denatured for 1 min at 941C and incubated for 30 cycles. Other procedures of polymerase chain reaction (PCR) and singlestrand conformation polymorphism (SSCP) analysis were performed as described previously. 8 After SSCP, DNAs showing mobility shifts were cut out from the dried gel, and reamplified for 30 cycles using the same primer sets. Sequencing of the PCR products was carried out using the cyclic sequencing kit (Perkin-Elmer, Foster City, CA) according to the manufacturer's recommendations.
SSCP analysis of the BRAF gene identified four aberrant bands in exon 11 (Figure 1 ). Enrichment and DNA sequence analysis of these aberrantly migrating bands led to the identification of four BRAF mutations (4.4%) (Figure 1 ). The BRAF mutations were observed in two of 10 B-cell ALLs (20%), one of 11 biphenotypic acute leukemias (9%) and one of 23 AMLs with maturation (4%). Of note, all of the four BRAF mutations involved codon 468 (G468A) in the G-loop domain (Figure 1) . None of the corresponding bone marrow samples after complete remission showed evidence of mutations by SSCP (Figure 1) , indicating the mutations detected in the specimens had risen somatically. We repeated the experiments two additional times, including PCR, SSCP and sequencing analysis to ensure the specificity of the results, and found that the data were consistent (data not shown).
In exon 15 of the BRAF gene, we could not detect any aberrant bands on SSCP. To confirm that our SSCP analysis was capable of detecting the most common BRAF mutation V599E, 2 we also analyzed DNA from the melanoma cell line SK-MEL-28 as a positive control for the V599E mutation. The SSCP from this cell line DNA showed aberrantly migrating bands (data not shown), indicating that the SSCP condition in this study could detect the V599E mutation.
Although the malignant melanoma is the most common tumor with BRAF mutations, it is known to possess a much lower frequency of RAS mutations.
1,2 Such differential occurrences of BRAF and RAS mutations in some human cancers led us to analyze BRAF mutation in leukemia in which RAS mutation is known to be a relatively common event. 3 We found that the BRAF gene is occasionally mutated in leukemias, indicating that the RAS-RAF kinase pathway in some leukemias may be regulated by somatic mutations of BRAF. Despite the low frequency of BRAF mutation in leukemias compared with that of malignant melanoma, our data suggest that alteration of the RAS-RAF kinase pathway by BRAF mutation may play an important role in leukemia carcinogenesis.
In the present study, none of the BRAF mutations involved the amino-acid V599. The data are quite contrast to those of malignant melanomas, where approximately 90% of BRAF mutations involved V599, 2 raising the possibility that the contribution of BRAF mutations in the development of leukemia might be different from that of malignant melanoma. Additionally, all of the four BRAF mutations in this study involved the same amino acid (G468) that is located in the GXGXXG motif within the G-loop of the kinase domain. The G468A mutation was proven to be an activating mutation by the kinase assay and the transformation assays. 2 The G468A mutation may represent a mutational hotspot in leukemias.
There is a difference in BRAF mutation frequency between the previous study that detected no BRAF mutation in 104 leukemias 3 and our study (four mutations in 90 leukemias) (Fisher's exact test, P ¼ 0.045). One of the possible explanations for this discrepancy could be the racial differences in the occurrences of BRAF mutation.
The most impressive examples of recent cancer therapies used protein kinase inhibitors such as Imanitib (Gleevec). 1 Since the RAS-RAF-MEK-ERK-MAP kinase pathway is activated by protein kinase, therapies that target this signaling pathway would therefore be very valuable in treating tumors that have activating mutations of BRAF. In this respect, the present study may provide the possibility of therapy targeting mutated BRAF in acute leukemias.
